Top 5 Quality Stocks To Own For 2015

In the past month or two, investors have gotten more comfortable with J.C. Penney’s (ticker: JCP ) turnaround plan. A theme running through the company’s earnings report and conference call this week was that J.C. Penney is “back,” and the turnaround is on track.

Indeed, it looks like J.C. Penney is starting to make real progress in its quest for sales and margin growth. It’s likely to take a big step forward during the holiday season, when it’s more important than ever to offer big eye-catching discounts — something the company didn’t do last year.

However, J.C. Penney is not in the clear, yet. I have never doubted that the company would eventually reverse its recent track record of sliding revenue and gross margin. The problem is simply that J.C. Penney is very far from the breakeven line, and it has been burning cash rapidly. In order to avoid bankruptcy, the company needs not just improvement, but rapid improvement.

Top 5 Quality Stocks To Own For 2015: Zimmer Holdings Inc.(ZMH)

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company offers orthopedic reconstructive devices that restore function lost due to disease or trauma in joints such as knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body?s natural healing process. It also provides surgical products comprising surgical supplies and instruments designed to aid in orthopedic surgical proce dures and post-operation rehabilitation. In addition, the company offers healthcare consulting services. Its customers include orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, and healthcare dealers, as well as agents, healthcare purchasing organizations, or buying groups. The company was founded in 1927 and is headquartered in Warsaw, Indiana.

Advisors’ Opinion:

  • [By Dan Carroll]

    One look around the industry this quarter tells the story. Zimmer Holdings (NYSE: ZMH  ) reported its own third-quarter results today. Zimmer’s hip sales grew by only 2%, and while growing knee product sales managed to lift the company’s quarterly revenue above expectations, the business hasn’t been enough to save Zimmer’s earnings from falling due to legal fees and other expenses. It’s a similar story at Stryker (NYSE: SYK  ) , another major rival in the orthopedics space. Stryker made a big move recently to purchase robotic orthopedic surgical firm MAKO Surgical to jump-start sales growth, and it’ll need the jolt. Stryker’s knee business grew revenue by only 2.1% in the third quarter, and while its hip sales managed strong growth, the firm will need its smaller, faster-growing businesses to continue to come through.

  • [By Ben Levisohn]

    Orthopaedics sales of $2.28B grew by 1.1% (all growth rates are Y/Y unless otherwise specified) constant currency (CC) vs. 3% CC organic growth in 2Q13 and missed consensus of $2.35B. JNJ’s worldwide hip growth was 6% CC vs. 4% CC in 2Q13 and its worldwide knee growth was 3% CC vs. 2% CC in 2Q13. We think JNJ’s results and commentary are positive for [Stryker (SYK) and Zimmer Holdings (ZMH)].

  • [By Dan Carroll]

    Despite all this, however, leading orthopedics firms have pushed on. Companies such as Stryker (NYSE: SYK  ) and Zimmer Holdings (NYSE: ZMH  ) have shown signs of hope for investors even while dealing with problems such as device recalls, but is this enough to warrant your investment in the orthopedics industry? Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss what you need to know about this industry in the video below.

  • [By Dan Carroll]

    The industry’s way of the future
    Emerging market trauma buys isn’t a new trend. Smith & Nephew follows in the footsteps of Stryker (NYSE: SYK  ) , its fellow orthopedics player that spent $764 million on purchasing China’s largest trauma business, Trauson Holdings, back in January. Zimmer Holdings (NYSE: ZMH  ) also took a step into China’s orthopedics market, purchasing Chinese firm Montagne back in 2010 to push its own emerging market expansion.

Top 5 Quality Stocks To Own For 2015: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company’s Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company’s lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it ex erts its localized anti-inflammatory and analgesic effect. Transdel is the Company’s transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors’ Opinion:

  • [By John Udovich]

    So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year – making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many…) planned biotech IPOs that have recently been announced publicly:

Top 5 Quality Stocks To Own For 2015: Excel Trust Inc (EXL)

Excel Trust, Inc., incorporated on December 15, 2009, is a vertically integrated, self-administered, self-managed real estate investment trust (REIT). The Company’s principal objective is to acquire, finance, develop, lease, own and manage value-oriented community and power centers, grocery anchored neighborhood centers and freestanding retail properties. The Company conducts all of its business through Excel Trust, L.P., a limited partnership, or its operating partnership. The Company operates through three reportable business segments: retail properties, multi-family properties and office properties. The multi-family segment consists of apartment units at one retail property, West Broad Village, which is located in Richmond, Virginia. The office segment consists of two properties, Excel Centre, a portion of which is utilized as its headquarters, and the Promenade Corporate Center. The Company is the sole general partner of its operating partnership. Excel Trust leases its properties to national and regional supermarket chains, big-box retailers and select national retailers that offer necessity and value oriented items and generate regular consumer traffic. In October 2012, the Company acquired six shopping centers. On January 24, 2013, the Company completed the acquisition of Tracy Pavilion, a retail shopping center with approximately 162,000 square feet of gross leasable area located in Tracy, California. In September 2013, the Company announced the sale of Grant Creek Town Center.

As of December 31, 2012, the Company owned a portfolio consisting of 30 retail properties totaling approximately 5.1 million square feet of gross leasable area, which were approximately 93.4% leased. The Company owns two commercial office properties, Excel Center, a portion of which is utilized as its corporate headquarters, and the Promenade Corporate Center. As of December 31, 2012, the Company had ownership interests in two unconsolidated reta il properties totaling 225,113 square feet of gross leasable! area, which were approximately 65.5% leased.

Advisors’ Opinion:

  • [By Marc Bastow]

    Commercial and retail property owner-operator and real estate investment trust Excel Trust (EXL) raised its quarterly dividend 3% to 17.5 cents per share, payable on Jan. 15 to shareholders of record as of Dec. 31.
    EXL Dividend Yield: 6.04%

Top 5 Quality Stocks To Own For 2015: ICON plc(ICLR)

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and rest of Europe. It specializes in strategic development, management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies. The company?s clinical research services include investigator recruitment, study monitoring and data collection, case report form preparation, patient safety monitoring, clinical data management, interactive voice response, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, and health economics. Its clinical research services also comprise marker access and commercialization services, strategic analysis and data operation, clinical pharmacology, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynam ic analysis, study protocol preparation, regulatory consulting, product development planning, strategic consulting, medical imaging, contract staffing, and electronic endpoint adjudication. In addition, the company offers various laboratory services, such as sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, and biomarker development. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

Advisors’ Opinion:

  • [By Louis Navellier]

    European Stocks to Buy: ICON Public Limited (ICLR)

    ICON Public Limited Company (ICLR) is a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, the United States, and Europe. They provide management, and analysis of programs that support various stages of clinical development process from compound selection to Phase I to IV clinical studies as well as lab services for companies conducting trials. The company has posted triple digit earnings gains and posted four consecutive positive earnings surprises in the past year. Analysts have been raising their estimates for the Irish company and Portfolio Grader raised the stock to an A last month. The stock is a strong buy at today’s price.

Top 5 Quality Stocks To Own For 2015: RAIT Financial Trust(RAS)

RAIT Financial Trust operates as a self-managed and self-advised real estate investment trust (REIT). The company, through its subsidiaries, invests in, manages, and services real estate-related assets with a focus on commercial real estate. It also offers a set of debt financing options to the commercial real estate industry along with fixed income trading and advisory services. In addition, RAIT Financial Trust owns and manages a portfolio of commercial real estate properties, and manages real estate-related assets for third parties. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. RAIT Investment Trust was founded in 1997 and is based in Philadelphia, Pennsylvania.

Advisors’ Opinion:

  • [By Marc Bastow]

    Commercial real-estate loan originator and real estate investment trust RAIT Financial Trust (RAS) raised its quarterly dividend 6% to 17 cents per share, payable April 30 to shareholders of record as of April 4. At more than an 8% yield, RAS stock has the highest yield on this week’s list of dividend stocks.
    RAS Dividend Yield: 8.14%.

  • [By Marc Bastow]

    Commercial real estate holding real estate investment trust (REIT) RAIT Financial (RAS) raised its quarterly dividend 7% to 16 cents per share, payable on Jan. 31 to share holders of record as of Jan. 7.
    RAS Dividend Yield: 7.48%

  • [By Eric Volkman]

    RAIT Financial Trust (NYSE: RAS  ) investors will be getting slightly more than they did last quarter, as a reward for putting their faith in the company (NYSE: RAS  ) . The real estate investment trust has declared a common stock dividend of $0.13 per share, to be handed out on July 31 to shareholders of record as of July 12. That amount is $0.01, or 8%, higher than RAIT’s previous distribution of $0.12, which was paid in April. Prior to that, the firm dispensed $0.10 per share.